Lessons from 20 years of medical cannabis use in Canada

Abstract

Background Canada was one of the first countries to regulate the medical use of cannabis. However, literature on Canada’s medical cannabis program is limited. Methods We use administrative data from the medical cannabis program, and licensed cannabis vendor catalog data to describe a) the participation of patients, physicians, and cannabis vendors in the program from its inception in 1999 to 2021, and b) trends in medical cannabis consumption, prices and potency. We also use national surveys conducted over the last several decades to estimate trends in regular cannabis use (medical or otherwise) and how it changed during the medical cannabis access regimes. Results In 2001, the Canadian government granted access to those with physician-documented evidence of a severe health problem that could not be managed using conventional therapies. Most patients accessed cannabis grown under a personal production license. By 2013, authorized daily cannabis dosages were very high. In 2014, the government, concerned over illegal diversion, required that cannabis be purchased from a licensed commercial grower; personal production was banned. Physicians were given responsibility for authorizing patient access. To fill the regulatory void, the physician regulatory bodies in Canada imposed their own prescribing restrictions. After these changes, the number of physicians who were willing to support patient cannabis use markedly decline but the number of patients participating in the program sharply increased. Medical cannabis use varied by province–rates were generally lower in provinces with stricter regulations on physician cannabis prescribing. Most varieties of cannabis oil available for sale are now high in CBD and low in THC. Dry cannabis varieties, conversely, tend to be high in THC and low in CBD. Inflation adjusted prices of most varieties of medical cannabis have declined over time. We find that rates of daily cannabis use (medical or otherwise) increased markedly after the 2014 policy regime. The fraction of Canadians using cannabis daily increased again after the 2018 legalization of recreational cannabis; at the same time, participation in the medical access program declined. Conclusion The implications for patient health outcomes of changes in the medical cannabis program and legalization of recreational use remains an important area for future research.

Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges

“…Between 2015 and 2019, the number of registered MC patients in Canada increased from 40,000 to nearly 400,000, an increase attributed to several policy changes that have gradually broadened access to a variety of medicinal cannabis formulations. In December 2015, the first cannabis oil product was launched in the Canadian market and in 2016, the Access to Cannabis for Medicinal Purposes Regulations allowed patients to grow cannabis for personal use [ 16 ].…”

“…Typically, the more readily accessible cannabis products are in the community, the lower the degree of purification and quality assurance. In light of high rates of self-reported use [ 16 , 46 , 48 ], this underscores the need to deliver evidence that (if shown to be beneficial) will ensure patients can access MC in more appropriate and safe formulations.…”

Distribution of legal retail cannabis stores in Canada by neighbourhood deprivation

“…While the number of brick and mortar stores was initially limited, there has been substantial growth to more than 2400 stores by September 2021 (Canadian Centre on Substance Use and Addiction 2022 ). Prior to the legalization of non-medical cannabis, medical cannabis was available to authorized users through home grow or mail order from a licensed producer who was regulated by Health Canada (Shim et al 2023 ). No ‘brick-and-mortar’ stores were permitted although some Canadian cities had unauthorized stores self-identifying as ‘medical dispensaries’ (Mahamad and Hammond 2018 ).…”

DNA methylation, but not microRNA expression, is affected by in vitro THC exposure in bovine granulosa cells

“…Likewise, Canadian youth have documented multiple reasons for using cannabis, including social anxiety, identity formation, social acceptability, perceived acceptability, and the lower perceived risk when compared to other substances [ 19 ]. In addition to the higher frequency of cannabis consumption, Δ 9 -Tetrahydrocannabinol (THC) potency in cannabis has also drastically increased from 4% in 1995 [ 11 ] to 20.5% in 2022 [ 20 , 21 ]. Likewise, the ratio of THC to cannabidiol (CBD) has drastically risen over the last 20 years [ 22 , 23 ].…”